Twilight of the stem cell transplant adjuncts?
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Which direction for Turning Point?
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
Affimed turns its back on T-cell recruitment
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Exact falls on Guardant’s liquid biopsy plans
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
Lundbeck leaps into the Tourette’s pipeline
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Pressure on Abbvie's pipeline grows
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
Novartis and Biogen face spinal muscular atrophy reckoning
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.
Eisai and Biogen throw good money after bad
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.